Top Markets
#1 Akedo Akedo +61.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.50%
#4 Cross Cross +46.58%
#5 Black Phoenix Black Phoenix +34.22%
#6 Velvet Velvet +31.90%
#7 OVERTAKE OVERTAKE +25.19%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.31%
#9 Not in Employment, Education, or Training Not in Employment, Education, or Training +14.54%
#10 Movement Movement +14.11%
Coin of the day
Akedo Akedo
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Redx Pharma Plc Redx Pharma Plc

Redx Pharma Plc

REDX
Classificação em ações #38811
Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in... Redx Pharma Plc, established in the United Kingdom in 2010 and headquartered in Macclesfield, concentrates its efforts on the discovery, early-stage preclinical development, and licensing of innovative small molecule drugs. The company primarily targets significant unmet medical needs in the therapeutic areas of oncology and fibrosis. Within its oncology portfolio, Redx is progressing RXC004, a porcupine inhibitor currently undergoing Phase II clinical evaluation for treating cancers driven by Wnt-ligands. Additionally, it maintains a research collaboration with Jazz Pharmaceuticals plc, aiming to identify and advance new drug candidates for two specific cancer pathways: the Ras/Raf/MAP kinase pathway. For fibrotic conditions, Redx Pharma is developing several compounds, including RXC007, an oral selective ROCK2 inhibitor intended for the treatment of various fibrotic diseases. Its pipeline also features a gastrointestinal-targeted ROCK inhibitor specifically designed to address fibrosis associated with Crohn's disease, along with a discoidin domain receptors (DDRs) inhibitor for a range of fibrotic disorders. Furthermore, the company is developing RXC006, another porcupine inhibitor, focused on combating fibrotic illnesses such as idiopathic pulmonary fibrosis.
Preço da ação
$0.20410523
Última sincronização: 2024-04-30
Valor de mercado
$793.94K
Variação (1 dia)
42.54%
Variação (1 ano)
0.00%
País
GB
Negociar Redx Pharma Plc (REDX)

Categoria

Healthcare
Receita da Redx Pharma Plc (REDX)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Redx Pharma Plc, a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Redx Pharma Plc de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE